A phase II study of gemcitabine combined with vinorelbine as first-line chemotherapy for metastatic breast cancer
BACKGROUND AND OBJECTIVES: There is an unmet need for new combination treatments, especially for aggressive, visceral, and high tumor burden metastatic breast cancer. Gemcitabine (GEM) has shown synergy with vinorelbine (VRL) in preclinical models, and has a toxicity profile that is different from V...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2010-01-01
|
| Series: | Hematology/Oncology and Stem Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1658387610500499 |